As a proof of concept, we analyzed the beneficial effects of pharmacologically modulating CRM1 in dermal fibroblasts from HGPS patients and the LMNAG609G/G609G mouse, using the first‐in‐class selective inhibitor of CRM1 termed selinexor. The gene discussed is XPO1; the disease is Hutchinson-Gilford progeria syndrome.